Communiqués Phio Pharmaceuticals Corp.

Actions

PHIO

US71880W5013

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 21:50:14 20/07/2026			Varia. 5j.	Varia. 1 janv.
1,080 ^USD	+4,85%		+7,13%	+2,03%

15/07	Phio Pharmaceuticals franchit une étape clé avec plusieurs avis d'acceptation et une décision de délivrance de brevets	CI
24/06	Phio Pharmaceuticals Corp. annonce le lancement de la production du premier lot cGMP à l'échelle commerciale du principe actif PH-762 chez Nitto Denko Avecia, Inc.	CI

Communiqués

15/07	Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision	NE
26/06	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE
25/06	Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026	NE
24/06	Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762	NE
18/06	Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026	NE
26/05	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE
12/05	Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside Chat with Force Family Office on Tuesday, May 19, 2026	NE
08/05	Phio Pharmaceuticals : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update	NE
23/04	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE
13/04	Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026	NE
09/04	Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026	NE
30/03	Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762	NE
23/03	Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement	NE
16/03	Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office	NE
10/03	Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT	AQ
10/03	Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT	NE
05/03	Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update	NE
05/03	Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series	NE
23/02	Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company	EQ
19/02	Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894	NE
10/02	Phio Announces Safety Monitoring Committee's (SMC) Positive Wrap-up on Lead Clinical Candidate PH-762 in Skin Cancer Trial	NE
26/01	Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference	NE
20/01	Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial	NE
15/01	Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026	NE